Skip to main content
. 2023 Jan 27;11(1):e005957. doi: 10.1136/jitc-2022-005957

Figure 5.

Figure 5

SARS-CoV-2 infections prior to anticipated CAR T-cell therapy. The timing of SARS-CoV-2 infection prior to planned CAR T-cell infusion and the delay in administration of planned CAR T-cell product is shown for eight patients, with each row representing one patient. CAR, chimeric antigen receptor.